Table 3 Missing data and exact agreement for variables included in the validation of the notification section of the Swedish National Register for Breast Cancer
From: Validation of data quality in the Swedish National Register for Breast Cancer
Variable in the Swedish National Register for Breast Cancer | Missing values in the NBCR (%) | Missing values in the medical records (%) | Missing values in both sources (%) | Exact agreement (%) | |
|---|---|---|---|---|---|
Diagnostics | Menstrual status | 62/799 (7.8) | 90/799 (11.3) | 28/799 (3.5) | 82.6 |
Laterality | 0/799 (0) | 0/799 (0) | 0/799 (0) | 98.5 | |
Initial contact (referral/mammography/self-admission) | 14/799 (1.8) | 7/799 (0.9%) | 0/799 (0) | 88.1 | |
Malignant diagnosis confirmed at first visit | 3/799 (0.4) | 29/799 (3.6) | 0/799 (0) | 83.5 | |
Screening detected | 5 /799 (0.6) | 3/799 (0.4) | 0/799 (0) | 94.9 | |
Malignant diagnosis confirmed preoperatively | 4/799 (0.5) | 43/799 (5.4) | 2/799 (0.3) | 91.2 | |
Base for diagnosis | 0/799 (0) | 0/799 (0) | 0/799 (0) | 77.9 | |
Preoperative multidisciplinary conference | 2/799 (0.3) | 2/799 (0.3) | 0/799 (0) | 95.2 | |
Stage | T classification | 1/799 (0.01) | 0/799 (0) | 0/799 (0) | 70.1 |
N classification | 0/799 (0) | 0/799 (0) | 0/799 (0) | 93.0 | |
M classification | 0/799 (0) | 0/799 (0) | 0/799 (0) | 98.6 | |
Planned care | Primary surgery planned | 0/799 (0) | 0/799 (0) | 0/799 (0) | 98.3 |
Reason for no primary surgery | 1/96 (1.0) | 5/96 (5.2) | 1/96 (1.0) | 53.1 | |
Primary systemic treatment | 5/799 (0.6) | 2/799 (0.3) | 0/799 (0) | 95.6 | |
Primary radiotherapy | 0/69 (0) | 0/69 (0) | 0/69 (0) | 100 | |
Primary endocrine therapy | 0/69 (0) | 0/69 (0) | 0/69 (0) | 95.7 | |
Primary chemotherapy | 0/69 (0) | 0/69 (0) | 0/69 (0) | 97.1 | |
Other primary systemic or targeted treatment | 0/69 (0) | 0/69 (0) | 0/69 (0) | 87.0 | |
Surgery | Final result breast surgery | 0/739 (0) | 1/739 (0.1) | 0/739 (0) | 95.9 |
Immediate breast reconstruction | 1/739 (0.1) | 1/739 (0.1) | 0/739 (0) | 98.5 | |
Contralateral surgery for symmetry | 3/739 (0.4) | 1/739 (0.1) | 0/739 (0) | 98.6 | |
Contralateral prophylactic surgery | 6/739 (0.9) | 1/739 (0.1) | 0/739 (0) | 96.2 | |
Sentinel node biopsy (SNB) | 0/739 (0) | 2/739 (0.3) | 1/739 (0.1) | 95.4 | |
Axillary surgery | 0/739 (0) | 1/739 (0.1) | 1/739 (0.1) | 90.9 | |
Final result axillary surgery | 0/701 (0) | 7/739 (0.9) | 2/739 (0.3) | 89.8 | |
Reoperative breast surgery | 1/739 (0.1) | 1/739 (0.1) | 0/739 (0) | 98.51 | |
Residual disease detected after reoperation | 2/63 (3.2) | 5/63 (7.9) | 1/63 (1.6) | 82.5 | |
Reoperative axillary surgery | 1/739 (0.1) | 5/739 (0.7) | 0/739 (0) | 96.9 | |
Reason for reoperative axillary surgery | 0/33 (0) | 9/33 (27) | 0/33 (0) | 57.6 | |
Reoperative surgery due to complications | 2/739 (0.3) | 2/739 (0.3) | 0/739 (0) | 96.6 | |
Histopathology | Basis for histopathological diagnosis | 3/799 (0.4) | 8/799 (1.0) | 1/799 (0.1) | 97.7 |
Invasiveness | 6/799 (0.8) | 21/799 (2.6) | 4/799 (0.5) | 86.0 | |
Type of invasive carcinoma | 2/688 (0.3) | 10/688 (1.5) | 1/688 (0.1) | 89.7 | |
Type of in situ carcinoma | 2/465 (0.4) | 23/465 (4.9) | 2/465 (0.4) | 87.5 | |
Number of invasive tumors | 7/644 (1.1) | 5/644 (0.8) | 0/644 (0) | 93.6 | |
Multifocality | 9/111 (8.1) | 5/111 (4.5) | 2/111 (1.8) | 76.6 | |
Number of sentinel nodes | 1/604 (0.2) | 2/604 (0.3) | 0/604 (0) | 91.0 | |
Metastasis in SN | 0/604 (0) | 12/604 (2.0) | 0/604 (0) | 93.9 | |
Number of SN with macrometastases | 2/119 (1.7) | 23/119 (19) | 1/119 (0.8) | 85.3 | |
Number of SN with micrometastases | 4/119 (3.4) | 41/119 (34) | 2/119 (1.7) | 82.9 | |
Number of SN with submicrometastases | 2/119 (1.7) | 53/119 (44.5) | 1/119 (0.8) | 89.2 | |
Nottingham Histological Grade or Nuclear Grade | 40/786 (5.1) | 50/786 (6.4) | 24/786 (3.1) | 88.9 | |
ER status | 41/786 (5.2) | 40/786 (5.1) | 10/786 (1.3) | 90.5 | |
PR status | 45/786 (5.7) | 48/786 (6.1) | 10/786 (1.3) | 85.2 | |
KI67 status | 85/786 (10.8) | 73/786 (9.3) | 85/786 (1.8) | 73.5 | |
HER2 status | 60/799 (7.5) | 84/799 (10.5) | 32/799 (4.0) | 73.3 | |
Presence of vascular invasion | 161/786 (20.5) | 175/786 (22.3) | 99/786 (12.6) | 79.8 | |
Postoperative treatment | Postoperative multidisciplinary conference | 3/739 (0.4) | 9/739 (1.2) | 1/739 (0.1) | 94.2 |
Planned postoperative adjuvant treatment | 1/739 (0.1) | 9/739 (1.2) | 1/739 (0.1) | 96.6 | |
Postoperative radiotherapy | 1/673 (0.1) | 12/673 (1.8) | 1/673 (0.1) | 95.5 | |
Radiotherapy to breast or chest wall | 0/519 (0) | 0/519 (0) | 0/519 (0) | 76.9 | |
Locoregional radiotherapy | 0/519 (0) | 0/519 (0) | 0/519 (0) | 87.1 | |
Endocrine treatment | 2/673 (0.3) | 14/673 (2.1) | 1/673 (0.1) | 93.8 | |
Antiestrogen | 0/532 (0) | 0/532 (0) | 0/532 (0) | 81.6 | |
Aromatase inhibitor | 0/532 (0) | 0/532 (0) | 0/532 (0) | 86.8 | |
Postoperative chemotherapy | 2/673 (0.3) | 12/673 (1.8) | 1/673 (0.1) | 94.8 | |
Anthracycline based | 0/232 (0) | 0/232 (0) | 0/232 (0) | 62.5 | |
CMF | 0/232 (0) | 0/232 (0) | 0/232 (0) | 94.8 | |
Taxanes | 0/232 (0) | 0/232 (0) | 0/232 (0) | 77.6 | |
Other chemotherapy | 0/232 (0) | 0/232 (0) | 0/232 (0) | 87.9 | |
Targeted therapy | 4/673 (0.6) | 14/673 (0.2) | 1/673 (0.1) | 95.5 | |
Trastuzumab | 0/59 (0) | 0/59 (0) | 0/59 (0) | 71.2 | |
Castration (medical) | 6/670 (0.9) | 20/673 (3.0) | 9/673 (0.3) | 96.3 | |